Overview
argenx is a global immunology company with its official seat in Amsterdam, the Netherlands, listed on Euronext Brussels and Nasdaq. Its medicine VYVGART (efgartigimod alfa), including VYVGART HYTRULO, is approved in more than 30 countries for generalized myasthenia gravis, CIDP and (in Japan) ITP. In August 2026 argenx reported positive Phase 3 results in autoimmune myositis and said it is preparing its commercial organization for launch; its US field team posts Neurology and Rheumatology Territory Business Manager roles.
Hiring snapshot
Hiring by specialty
Open roles
Newest first, from argenx’s careers page.
- Rheumatology Territory Business Manager, Northern New JerseyPaterson, New JerseyYesterday$140k–$193k
- Rheumatology Territory Business Manager, Portland, MEPortland, Maine3d ago$140k–$193k
- Field Reimbursement Manager, Mid-Atlantic EastLocation not listed3d ago
- Field Reimbursement Manager, West AtlantaLocation not listed4d ago$176k–$242k
- Field Reimbursement Manager, PhillyLocation not listed4d ago$176k–$242k
- Field Reimbursement Manager, New EnglandSpringfield, Massachusetts4d ago$176k–$242k
Divisions
Division information is pending company verification.Once argenx claims its page, you will see each division, who it calls on and how it pays.
Claim your pageMore from argenx
These sections fill in when argenx claims and verifies its page.